[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Tuesday Afternoon",
    "summary": "Health care stocks were mixed in Tuesday afternoon trading, with the NYSE Health Care Index easing 0",
    "url": "https://finnhub.io/api/news?id=1ad9da57cdbebaf112d43304ecb6b583b0893f43127c203d77f4dd7d36618b74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735062464,
      "headline": "Sector Update: Health Care Stocks Mixed Tuesday Afternoon",
      "id": 132139046,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed in Tuesday afternoon trading, with the NYSE Health Care Index easing 0",
      "url": "https://finnhub.io/api/news?id=1ad9da57cdbebaf112d43304ecb6b583b0893f43127c203d77f4dd7d36618b74"
    }
  },
  {
    "ts": null,
    "headline": "3 biggest catalysts expected for healthcare in 2025",
    "summary": "After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=d257b317d5d05997105840bc14ccb6a93eae24c968c53d9f1a66458a6df399af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735060800,
      "headline": "3 biggest catalysts expected for healthcare in 2025",
      "id": 132133934,
      "image": "https://s.yimg.com/ny/api/res/1.2/beEG94ULzRzpQ6PW9JqZAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/664ed980-c215-11ef-af3f-16c0199a30a2",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=d257b317d5d05997105840bc14ccb6a93eae24c968c53d9f1a66458a6df399af"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock rises Tuesday, still underperforms market",
    "summary": "Pfizer Inc. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=3b6ebbf2d496665f10daf72f3f0a05af3c285c0de159d07e455e1fda51449af1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735058340,
      "headline": "Pfizer Inc. stock rises Tuesday, still underperforms market",
      "id": 132147561,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=3b6ebbf2d496665f10daf72f3f0a05af3c285c0de159d07e455e1fda51449af1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Time And Patience Ran Out (Rating Downgrade)",
    "summary": "Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained turnaround is close for PFE stock.",
    "url": "https://finnhub.io/api/news?id=5bb5d990ccf7462017b856c1ce4722c823d4235433be26b2bab9f8c820190d1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735029000,
      "headline": "Pfizer: Time And Patience Ran Out (Rating Downgrade)",
      "id": 132131133,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained turnaround is close for PFE stock.",
      "url": "https://finnhub.io/api/news?id=5bb5d990ccf7462017b856c1ce4722c823d4235433be26b2bab9f8c820190d1d"
    }
  },
  {
    "ts": null,
    "headline": "Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer",
    "summary": "By Adriano Marchese Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of...",
    "url": "https://finnhub.io/api/news?id=52801a65cd7168969f3c3a17b185dce92c3c8dd6538768c493b63a17e63230da",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735026010,
      "headline": "Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer",
      "id": 132130451,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Adriano Marchese Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of...",
      "url": "https://finnhub.io/api/news?id=52801a65cd7168969f3c3a17b185dce92c3c8dd6538768c493b63a17e63230da"
    }
  },
  {
    "ts": null,
    "headline": "If You Could Only Buy One: 5 Top Dividend Stocks For The Next 10 Years",
    "summary": "I asked followers to select a single stock for a 10-year investment horizon. Check out the long-term prospects of each stock pick.",
    "url": "https://finnhub.io/api/news?id=bcdd051a9c18e3046a84d0d47e672f3fa98a094ef6308c8ab3e95b1581ed80f3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735025400,
      "headline": "If You Could Only Buy One: 5 Top Dividend Stocks For The Next 10 Years",
      "id": 132130428,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/170521142/image_170521142.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I asked followers to select a single stock for a 10-year investment horizon. Check out the long-term prospects of each stock pick.",
      "url": "https://finnhub.io/api/news?id=bcdd051a9c18e3046a84d0d47e672f3fa98a094ef6308c8ab3e95b1581ed80f3"
    }
  }
]